Here is how Axon Enterprise (AXON) and Flowserve (FLS) have performed compared to their sector so far this year.
In a politically divisive environment, about the one thing that Americans can agree on is that the men and women who protect our communities deserve the equipment and assets necessary to do their job. That's where security specialist Axon Enterprise (NASDAQ: AXON ) enters the frame.
Despite the recent stock market sell-off, Taser maker Axon stock, along with Howmet and Tenet Healthcare, are near buy points.
Axon Enterprise's (AXON) Q2 revenues increase 34.6% year over year, driven by the impressive performance of its Software & Sensors and TASER segments.
Although the revenue and EPS for Axon (AXON) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Axon Enterprise (AXON) came out with quarterly earnings of $1.20 per share, beating the Zacks Consensus Estimate of $1.06 per share. This compares to earnings of $1.11 per share a year ago.
Axon Enterprise raised its full-year revenue forecast on Tuesday, banking on strong demand for its software products and recently launched TASER 10 policing device, sending its shares up 4.7% in aftermarket trading.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Beyond analysts' top -and-bottom-line estimates for Axon (AXON), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
Recently, Zacks.com users have been paying close attention to Axon (AXON). This makes it worthwhile to examine what the stock has in store.
Axon Enterprise (AXON) closed the most recent trading day at $304.72, moving -1.39% from the previous trading session.
Axon (AXON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.